Under constraction
Monday, July 18, 2016
Popular Posts
-
GOOD PRACTICES FOR DATA MANAGEMENT AND INTEGRITY IN REGULATED GMP/GDP ENVIRONMENTS This document was written with the aim of: Provid...
-
Each person engaged in the manufacture, processing, packing, or holding of a drug product shall have education, traini...
-
The U.S. Food and Drug Administration (FDA) inspected Chinese firm M/s Baoying County Fukang Medical Appliance Co. revealed se... -
On 22 November, 2016, the US Food and Drug Administration (FDA) finalized its long awaited Guidance on Contract Manufacturer Quality...
-
The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Shandong Analysis and Test Center at 19... -
The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, USV Private Limited at H-17/H-18, OIDC, Mahatma... -
The US Food and Drug Administration (FDA) on Tuesday released a warning letter sent 10 April to Teva for deficiencies related to an ac... -
www.gmpviolations.com This FDA has been issued a Warning Letter to the Chinese manufa... -
The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Hospira Inc., a Pfizer Company at 1776 Centenn... -
A medicinal product authorization application requires comprehensive information on origin and quality of an active substance. What inf...
-
FDA Warning Letters go to Manufacturers in China, Ireland, Australia and India In the Month of May-2018 The US FDA has i... -
FDA Guide to Equipment design, size, and location 211.63 Subpart D--Equipment Sec. 211.63 Equipment design, size, and location ...
-
Featured Post
FDA Guideline to 21 CFR PART 211 SUB PART-D EQUIPMENT #21CFR #PART211 #EQUIPMENT #PBS #PBSINDIA
FDA Guideline to 21 CFR PART 211 SUB PART-D EQUIPMENT #21CFR #PART211 #EQUIPMENT #PBS #PBSINDIA GMP News, GMP guidelines,...
-
FREE GMP NEWS
Subscribe To
Posts
Comments
0 comments:
Post a Comment